Advertisement

Aiming for Global Safety Net—An Interpretation and Lessons

  • Satoru Kimura
  • Yasuhide Nakamura
Chapter
Part of the Trust book series (TRUST, volume 5)

Abstract

Global-scale dissemination and distribution of poor quality pharmaceuticals is the “problem” that threatens profits of pharmaceutical companies in developed countries and, at the same time, is the “problem” that threatens public health in emerging and developing countries. The two “problems” become intertwined with each other to produce a complex phenomenon, which shows different aspects when viewed at different angles and can be interpreted differently. The economy of a single state consists of four units, i.e., foreign countries, government, companies, and household budgets. The aggregate of these units forms regional and international societies. The problem of poor quality pharmaceuticals results from mutual economic activities between formal and informal sectors both inside individual countries and in the international society. When arguing public health as a horizontal axis and the actual situations and challenges in the four units as a vertical axis, we should have a pluralistic perspective. Ultimately, we end up with reaching the question: What are our values so as to have better behavioral principles.

Keywords

Informal sector Political commitment Public health Safety net 

References

  1. Africa Japan Forum. 2003. Koeizuyaku he no Akusesu [Access to Anti-HIV Drugs]. https://www.google.com/search?hl=ja&hq=inurl%3Awww.ajf.gr.jp&ie=Shift_JIS&oe=Shift_JIS&filter=0&q=TRIPs&submit.x=8&submit.y=9. (In Japanese). Accessed 22 March 2014.
  2. Alfadl, A.A., M.A. Hassali, and M.I. Ibrahim. 2013. Counterfeit drug demand: perceptions of policy makers and community pharmacists in Sudan. Research in Social and Administrative Pharmacy 9(3): 302–310.  https://doi.org/10.1016/j.sapharm.2012.05.002. https://www.ncbi.nlm.nih.gov/pubmed/22835708. Accessed 1 September 2018.CrossRefGoogle Scholar
  3. FDA. 2013. FDA prohibits manufacture of FDA-regulated drugs from Ranbaxy’s Mohali, India, plant and issues import alert. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm368445.htm. Accessed 13 December 2016.
  4. Ginger, Z.J. 2014. Poor quality drugs in global health. Maryland Center for Economics and Policy. http://mcep.umd.edu/project/poor-quality-drugs-global-health. Accessed 16 September 2015.
  5. IFPMA. 2016. Intanetto Hanbai to Anzenna Iyakuhin Akusesu ni Kansuru IFPMA/PhRMA/EFPIA/JPMA no Kyodo Seimei ni Tsuite [Joint Announcement by IFPMA/PhRMA/EFPIA/JPMA on Internet Sales and Safe Access to Medicines]. http://www.jpma.or.jp/event_media/release/pdf/120724_01_j.pdf. (In Japanese) Accessed 8 September 2016.
  6. Institute for Health Economics and Policy. 2015. Shin Keizai Seicho no Iryo Hosho Seido ni kansuru Chosa Kenkyu -Indo no Iryo Hosho Seido- Hokokusho [Survey Research on Medical Security Systems—the Medical Security System in India—Report]. Institute for Health Economics and Policy, Association for Health Economics Research and Social Insurance and Welfare, a General Incorporated Foundation: Tokyo, Japan. (In Japanese).Google Scholar
  7. Kamiike, Atsuko, and Takahiro, Sato. 2006. WTO no Boeki Kanren Chiteki Shoyuken (TRIPS) Kyotei to Indo Iyakuhin Sangyo [WTO trade-related intellectual property rights (TRIPS) agreement and pharmaceutical industry in India]. JCAS 7(2): 149–167. http://www.cias.kyoto-u.ac.jp/files/img/publish/alpub/jcas_review/JCAS_Review_07_02/JCAS_Review_07_02_009.pdf (In Japanese). Accessed 26 August 2018.
  8. Kamiike, Atsuko. 2007. Indo Iyakuhin Sangyo ga Kakaeru Kadai [Challenges to be Addressed by the Pharmaceutical Industry of India], ed. Kubo, Kensuke, 55–79. Chiba: Nihon no Jenerikku Iyakuhin Sangyo to Indo, Chugoku no Seiyaku Sangyo [Generic Medicine Industry in Japan and Pharmaceutical Industry in India and China]. IDE-JETRO. (In Japanese).Google Scholar
  9. Kato, Akiko. 2003 Progressive development of protection framework for pharmaceutical invention under the TRIPs agreement: focusing on patent rights. Bulletin of Institute of Intellectual Property. http://www.iip.or.jp/summary/pdf/detail02j/14_19.pdf. Accessed 4 September 2016.
  10. Kaul, Inge., Grunberg, Isabelle., and Stern, Marc A. 1999. Global Public Goods—International Cooperation in the 21st Century. Trans. United Nations Development Programme.Google Scholar
  11. Kobayashi, Tatsuya. 1981. Gijutsu Iten -Rekishi kara no Kosatsu: Amerika to Nihon [Technology Transfer—Discussion from History: USA and Japan]. Tokyo: Bunshindo. (In Japanese).Google Scholar
  12. Meadows, Donella H. 2008. Thinking in Systems: A Primer. Trans. USA: Sustainability Institute.Google Scholar
  13. Minato, Kazuki. 2007. Indo Seiyaku Sangyo—Hatten no Seidoteki Haikei to TRIPS Kyoteigo no Henka [Pharmaceutical Industry in India: The Institutional Background of Development and Changes after TRIPS Agreement]. ed. Kubo Keisuke, 21–54. In Nihon no Jenerikku Iyakuhin Shijo to Indo, Chugoku no Seiyakusangyo [Generic drug market in Japan and Pharmaceutical industry in India and China]. Chiba: IDE-JETRO. (In Japanese).Google Scholar
  14. Moisi, Dominique. 2009. The Geopolitics of Emotion. Trans: Doubleday.Google Scholar
  15. Mori, Makoto. 1994. Tokkyo no Bunmeishi [History of patents from the perspective of civilization]. Tokyo: Shinchosya. (In Japanese).Google Scholar
  16. MSF. Kusuri no Nyushu wo Habamu Kabe no Kokufuku [Challenges to the Wall that Blocks Access to Medicines]. http://www.msf.or.jp/about/access_campaign/overcome.html. (In Japanese) Accessed 9 October 2016.
  17. Nakaoka, Tetsuro. 2002. Sengo Nihon no Gijutsukeisei [Technology Development in Post War Japan -Imitation or Creation-]. Tokyo: Nihonkeizai Hyoronsya. (In Japanese).Google Scholar
  18. Neuwirth, Robert. 2011. Stealth nations: the global rise of the informal economy. Trans. New York: Pantheon Books.Google Scholar
  19. Osawa, Toshihiko. 2008. TRIPS-PLUS strategy of the US, Journal of Intellectual Property Association of Japan 5(1): 55–56.Google Scholar
  20. Suwa, Yoshihiro. 2014. Kokumin Kaihoken heto Ugokidashita Indonesia HerusuKea Sangyo no Miryoku to Otoshiana [Attractive Points and Pitfalls of Healthcare Industry in Indonesia Moving Towards Universal Health Insurance Coverage]. ITmedia Executive. http://mag.executive.itmedia.co.jp/executive/articles/1406/02/news014_4.html. (In Japanese) Accessed 1 September 2018.
  21. WHO. 1996. World health report 1996—fighting disease, fostering development. http://www.who.int/whr/1996/en/. Accessed 26 August 2018.
  22. WHO. 1997. World health report 1997—conquering suffering, enriching humanity. http://www.who.int/whr/1997/en/. Accessed 26 August 2018.
  23. WHO. 2006. WHA59.24. Public health, innovation, essential health research and intellectual property rights: towards a global strategy and plan of action. http://apps.who.int/medicinedocs/documents/s21428en/s21428en.pdf#search=%27WHO.+2006.+WHA59.24%. Accessed 27 October 2014.
  24. WHO. 2016. Global tuberculosis report 2016. http://apps.who.int/iris/bitstream/10665/250441/1/9789241565394-eng.pdf?ua=1. Accessed 13 December 2016.
  25. Yamane, Hiroko. 2008. Chiteki Zaisanken no Gurobaruka -Iyakuhin Akusesu to TRIPS Kyotei- [Globalization of Intellectual Property Rights -Access to Medicines and TRIPS Agreement-]. Tokyo: Iwanamishoten. (In Japanese).Google Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2020

Authors and Affiliations

  • Satoru Kimura
    • 1
  • Yasuhide Nakamura
    • 2
  1. 1.Department of Reference StandardsPharmaceutical and Device Regulatory Science Society of JapanOsakaJapan
  2. 2.School of Nursing and RehabilitationKonan Women’s UniversityKobeJapan

Personalised recommendations